Cerebras Systems Inc. (CBRS) is a Sunnyvale, California-based AI infrastructure company that builds wafer-scale processors and rack-scale compute systems, and increasingly sells inference capacity through its own cloud and third-party hyperscalers. In early trading on Monday, the stock was changing hands at $101.90, down 6.27% from Friday's close of $108.72. The direction was decisively negative. The immediate driver was a wave of analyst price-target reductions published over the weekend following last Thursday's third-quarter report, combined with profit-taking after Friday's double-digit rebound.
Cerebras reported third-quarter results after Thursday's close, and the initial reception was enthusiastic. Core revenue reached a record $230.9 million, up 70% year over year, GAAP revenue rose 55% to $210.8 million, and management raised full-year 2026 core revenue guidance to $940 million–$960 million. Fourth-quarter guidance of $310 million–$330 million in core revenue implied roughly 39% sequential growth. Shares responded with an 11.22% jump on Friday, closing at $108.72 after touching $120.44 intraday.
That rally created a large, fast gain in a stock with a battered shareholder base. With the shares still far below their $185 IPO price and their May peak, Friday's spike drew sellers looking to exit near the top of a violent two-week bounce off the $77.84 low set on November 5. Monday's decline is consistent with that pattern: a sharp counter-trend rally meeting overhead supply rather than a fresh fundamental shock.
The clearest verified catalyst behind Monday's weakness was the weekend recalibration of Street models. Needham maintained a Buy rating but cut its target to $200 from $300. UBS kept a Buy while slashing its target to $155 from $250. Mizuho retained an Outperform rating and trimmed its target to $240 from $300. All three remain constructive on the name, but the direction of the revisions was uniformly lower, and the magnitude of the reductions signaled that even bullish analysts are marking down the multiple they will pay for Cerebras' growth.
The underlying tension is the gap between the headline beat and the accounting reality. GAAP loss per share of $0.67 missed the consensus loss of $0.14, GAAP revenue of $210.8 million came in slightly below the $214.7 million estimate, and GAAP gross margin was just 20%. Core operating losses totaled $33.1 million. Management also disclosed that the first tranche of capacity for its largest customer is behind schedule because data-center buildings and power are not ready, with cloud revenue guided roughly flat sequentially for the fourth quarter and most new capacity arriving in mid-2027. A single customer relationship tied to roughly $20 billion of contracted business makes those delays disproportionately important to the equity story.
Over the weekend, two law firms issued notices that they are investigating potential claims on behalf of Cerebras shareholders, adding a legal-and-sentiment layer to the post-earnings narrative. The stock is also digesting a lock-up that fully expired on November 9, with the vast majority of restricted shares having been released in stages through late October. A larger tradeable float in a stock already absorbing a critical short-seller report does not, by itself, force selling — but it removes a structural prop from the share price.
The move was company-specific rather than sector-driven. Cerebras has traded as an idiosyncratic story for months, diverging from larger AI chip peers such as NVDA as investors rotated toward established leaders and questioned Cerebras' customer concentration. Options activity has concentrated in near-term downside strikes, reflecting persistent hedging demand.
Turnover has been extraordinary. Friday's session saw more than 21 million shares change hands against a roughly 4.9 million-share average over the past 70 sessions. From a technical standpoint, the shares failed at the $108–$120 resistance band formed by Friday's range and slipped back below their 20-day moving average near $105. The next reference points are the $96–$98 shelf and the November 5 low of $77.84, with market capitalization now near $24 billion.
The score is measured on a scale where 0 means no meaningful news and a move typical for the stock, and 100 means transformative news paired with an extreme, rare price move. Cerebras earns 21 out of 100.
The verified news was moderate: coordinated analyst price-target cuts after a mixed quarterly report matter, but no rating was downgraded and no guidance was withdrawn, and the fundamental trajectory — 70% core revenue growth and a raised full-year outlook — was unchanged. The price move was unremarkable by this stock's standards. At 6.27%, it was roughly 1.3 times the 4.8% average absolute daily move, and 19 of the past 69 sessions produced moves of equal or greater size. Modest news and an ordinary-sized move for a highly volatile name combine into a low score.
Attention turns to the fourth-quarter report, expected in February, where guidance calls for core revenue of $310 million–$330 million, core gross margin of 47%–49%, and roughly break-even core operating results. Investors will focus on whether Oracle shipments land as planned, whether Microsoft-related revenue begins contributing as scheduled in the first half of 2027, and whether data-center capacity turns live on time. Management's target of tripling revenue in 2027 and reaching a 60% long-term gross margin remains the central debate. Risks include further customer-concentration disclosures, cancellation clauses tied to delays, dilution from stock-based compensation, and the possibility of formal litigation.
Tickeron's Trending AI Robots page curates the automated strategies that are performing strongest under present market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and only the top performers earn a place in this featured section. Bots differ widely by strategy logic, holding period, performance metrics, and the symbols they trade, so the lineup rotates as market conditions shift. Reviewing the current leaders is a practical way to see which approaches are adapting best to today's volatile tape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CBRS declined for three days, in 28 of 28 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CBRS entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 5 of 5 cases where CBRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for CBRS just turned positive on November 09, 2026. Looking at past instances where CBRS's MACD turned positive, the stock continued to rise in 1 of 2 cases over the following month. The odds of a continued upward trend are 50%.
Following a +18.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBRS advanced for three days, in 17 of 22 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CBRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.327) is normal, around the industry mean (5.443). P/E Ratio (-19.264) is within average values for comparable stocks, (15.640). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.803). Dividend Yield (0.000) settles around the average of (0.014) among similar stocks. P/S Ratio (63.694) is also within normal values, averaging (46.468).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CBRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Semiconductors